BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Vaughan KL, Tweedie D, Jung J, Kim HK, Choi HI, Kim DS, Mattison JA, Greig NH. Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon. Sci Rep 2019;9:17208. [PMID: 31748513 DOI: 10.1038/s41598-019-53356-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ. The effect of GLP-1RA exenatide on Idiopathic Intracranial Hypertension: Randomised Clinical Trial.. [DOI: 10.1101/2022.05.24.22275518] [Reference Citation Analysis]
2 Shang P, Baker M, Banks S, Hong SI, Choi DS. Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists. J Mov Disord 2021;14:193-203. [PMID: 34399565 DOI: 10.14802/jmd.21035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Ge Y, Hu Z, Chen J, Qin Y, Wu F, Jin T. Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide. Pharmaceutics 2021;13:816. [PMID: 34070856 DOI: 10.3390/pharmaceutics13060816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Tully M, Wedepohl S, Kutifa D, Weise C, Licha K, Schirner M, Haag R. Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates. Eur J Pharm Biopharm 2021;164:105-13. [PMID: 33957224 DOI: 10.1016/j.ejpb.2021.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Esparza-Salazar FJ, Lezama-Toledo AR, Rivera-Monroy G, Borlongan CV. Exendin-4 for Parkinson's disease. Brain Circ 2021;7:41-3. [PMID: 34084977 DOI: 10.4103/bc.bc_21_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci 2021;4:858-69. [PMID: 33860208 DOI: 10.1021/acsptsci.1c00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Kamath SM, Sridhar K, Jaison D, Gopinath V, Ibrahim BKM, Gupta N, Sundaram A, Sivaperumal P, Padmapriya S, Patil SS. Fabrication of tri-layered electrospun polycaprolactone mats with improved sustained drug release profile. Sci Rep 2020;10:18179. [PMID: 33097770 DOI: 10.1038/s41598-020-74885-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
8 Yu SJ, Chen S, Yang YY, Glotfelty EJ, Jung J, Kim HK, Choi HI, Choi DS, Hoffer BJ, Greig NH, Wang Y. PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. Front Neurosci 2020;14:785. [PMID: 32848559 DOI: 10.3389/fnins.2020.00785] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]